Streetbeat News

APLIF

Appili Therapeutics Inc

Industry

Pharmaceutical Preparation Manufacturing

Open

0.03

Mkt cap

3.4M

Volume

High

0.03

P/E Ratio

-1.40

52-wk high

0.05

Low

0.03

Div yield

N/A

52-wk low

0.01

Aditxt, Inc. (NASDAQ:ADTX) has signed a second amendment to its arrangement agreement with Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF), targeting a September 30, 2024, closing for the acquisition. Appili has raised CAD $100M for developing therapeutics for infectious diseases and biodefense markets, with two programs potentially eligible for FDA Priority Review Vouchers.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.